Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Protein in Brain Linked with Obesity and Insatiable Appetite in Mice

Researchers from the Okinawa Institute of Science and Technology Graduate University (OIST) have identified a protein that plays a key role in how the brain regulates appetite and metabolism. Their studies in rodents demonstrated that loss of the protein, XRN1

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers from the Okinawa Institute of Science and Technology Graduate University (OIST) have identified a protein that plays a key role in how the brain regulates appetite and metabolism. Their studies in rodents demonstrated that loss of the protein, XRN1, from the forebrain, leads to extreme appetite and obesity in mice. Mice without XRN1 were resistant to the appetite-suppressing hormone, leptin, and to insulin, and demonstrated increased activity of a type of neuron in the hypothalamus that releases the appetite stimulant, AgRP.

The team said their results could have implications for future obesity treatment strategies. “Identifying which neurons and proteins in the brain are involved in regulating appetite, and fully determining how resistance to leptin is caused, could eventually lead to a targeted treatment for obesity,” said Akiko Yanagiya, PhD, a researcher in the Cell Signal Unit at OIST, headed by Tadashi Yamamoto, PhD.

The researchers reported their findings in iScience, in a paper titled, “Neuronal XRN1 is required for maintenance of whole-body metabolic homeostasis.”

Obesity is a growing public health concern, with over 650 million adults worldwide designated as obese. The condition is linked with disorders including cardiovascular disease, type 2 diabetes, and cancer. “Fundamentally, obesity is caused by an imbalance between food intake and energy expenditure,” said Yanagiya, “But we still understand very little about how appetite or metabolism is regulated by communication between the brain and parts of the body, such as the pancreas, liver, and adipose tissues.”

When a gene is active, DNA is transcribed into a molecule of mRNA, which can then be used to build a specific protein. Cells have many ways of regulating the activity of genes, one of which is by degrading mRNA more slowly or more quickly, which results in either more or less protein, respectively, being produced. XRN1 plays a crucial role in gene activity, as it is involved in the last step of degrading mRNA.

For their reported study, the scientists created mice that were unable to produce XRN1 in a subset of neurons in the forebrain (Xrn1-cKO mice). This brain region includes the hypothalamus, an almond-sized structure that releases hormones into the body, helping to regulate body temperature, sleep, thirst, and hunger. The hypothalamus integrates inputs from various peripheral tissues and regulates feeding and energy expenditure, the authors pointed out. “Therefore, various studies have sought to identify hypothalamic nuclei and neuropeptides involved in eating and regulation of energy metabolism.”

The scientists noticed that at six weeks old, the Xrn1-cKO mice that lacked forebrain XRN1 rapidly began to gain weight and they became obese by 12 weeks of age, with fat accumulating in the animals’ adipose tissue and liver. And when the team monitored feeding behaviour in the mice, they noticed that those lacking forebrain XRN1 ate almost twice as much each day as the control mice.

“This finding was really surprising,” said Shohei Takaoka, PhD, a former student from the OIST Cell Signal Unit. “When we first knocked out XRN1 in the brain, we didn’t know exactly what we would find, but this drastic increase in appetite was very unexpected.”

The video shows two mice, one of which is normal weight. The other mouse is obese, due to a loss of XRN1 in the forebrain. These mice were part of a recent iScience study, with the video appearing in the associated press release, “Key protein linked to appetite and obesity in mice.” [OIST]

To investigate what might be causing the mice to overeat, the scientists measured the blood levels of leptin—a hormone that suppresses hunger. Compared to the controls, the level of leptin in the blood of the knockout mice was abnormally high, which would normally stop the mice from feeling hungry. “Serum leptin was already significantly increased in 5-week-old Xrn1-cKO mice compared to control mice, suggesting that alteration of peripheral metabolic signals had already developed before the onset of obesity,” the team noted. But unlike the control mice, the mice without XRN1 didn’t respond to the presence of leptin—a condition known as leptin resistance.

The scientists also found that 5-week-old mice were resistant to insulin, which is released by beta cells in the pancreas in response to the high levels of blood glucose that occur after eating. This type of failure in how the body responds to glucose and insulin can ultimately lead to diabetes. And as Xrn1-cKO got older, levels of glucose and insulin in their blood rose significantly, alongside the increased leptin levels.

“Moreover, glucose tolerance was impaired in 5-week-old Xrn1-cKO mice compared to control mice, indicating that glucose metabolism is dysregulated in Xrn1-cKO mice,” the investigators confirmed. “Furthermore, 5-week-old Xrn1-cKO mice exhibited insulin resistance, suggesting that insulin sensitivity is impaired in Xrn1-cKO mice. Weight gain, food intake, and metabolic dysregulation such as impaired glucose tolerance and insulin resistance developed as early as 5 weeks old in Xrn1-cKO mice, before the onset of increased body weight.”

“We think that the levels of glucose and insulin rose due to the lack of response to leptin,” explained Yanagiya. “Leptin resistance meant that the mice kept eating, keeping the level of glucose in the blood high, and therefore increasing insulin in the blood.”

The team in addition checked whether the obesity was also driven by the mice using less energy. They placed each mouse in a special cage that measured how much oxygen the mice used, which allowed them to indirectly work out the animal’s metabolic rate. They found no overall difference in energy expenditure between the 6-week-old control and XRN1-deficient mice. However, the animals lacking XRN1 in the forebrain were mainly using carbohydrates as an energy source, while the control mice were able to switch between burning carbohydrates at night, when they were most active, and fat during the day, when they were less active. “Xrn1-cKO mice do not exhibit the diurnal switch from carbohydrate to fat usage …” they wrote. “For some reason, this means that without XRN1, the mice cannot use fat as a fuel effectively,” said Yanagiya. “Why this occurs though, we still don’t know.”

At 12 weeks of age the XRN1-deficient animals did start to exhibit comparatively decreased energy expenditure but, the scientists believed, this was an effect of obesity, due to the mice being less active, rather than a cause. “Overall, we think overeating due to leptin resistance was the driving cause behind why these mice became obese,” noted Yanagiya.

To further investigate how loss of XRN1 results in leptin resistance and an increased appetite, the scientists then looked for any change in activity of appetite-regulating genes in the hypothalamus. They found that the mRNA used to make the protein Agouti-related peptide (AgRP)—one of the most potent stimulators of appetite—was elevated in the obese mice, leading to higher amounts of AgRP protein. “Because leptin acts primarily via AgRP neurons to regulate body weight and food intake, it is feasible that leptin resistance in Xrn1-cKO mice might originate from activated AgRP neuron,” they suggested.

The exact mechanism by which loss of XRN1 leads to increased activation of AgRP neurons remains unclear. Even so, Yanagiya noted, “It’s still only speculation, but we think that an increase of this protein, and abnormal activation of the neuron that produces it, might be the cause of leptin resistance in these mice. Leptin normally suppresses activity of the AgRP neuron, but if loss of XRN1 results in this neuron remaining highly active, it could override the leptin signal.”

XRN1 was removed only in a specific subset of neurons in the forebrain, and these don’t include AgRP neurons. This suggests that another neuron that did lose XRN1 may be involved and could be signaling incorrectly to the AgRP neurons and keeping them active. Moving forward, the lab hopes to collaborate with neuroscience research units, in order to pinpoint exactly how XRN1 impacts the activity of neurons in the hypothalamus to regulate appetite. And as the authors concluded, “understanding the molecular mechanisms of obesity and energy homeostasis regulated by XRN1 may enable development of novel therapeutic strategies for metabolic disorders such as obesity and diabetes.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What roles does the system play?

The endogenous opioids and their receptors are widely distributed throughout the central and peripheral nervous systems, particularly the parts of these systems that regulate pain, emotion, reward, stress responses, motivation, drug addiction, and autonomic control. The differential expression and location of the various receptor subtypes across different neurons account for the wide range of opioid-related behaviors. The activation of µ-opioid receptors is mainly known for playing a role in pain relief. Still, research has also indicated it may be involved in behaviors related to survival, such as appetite and reproduction. The activity of µ-opioid receptors is also known to play a critical role in responses to social stimuli by modulating responses to social rejection or social acceptance, for example. Activation of the δ-opioid receptors and κ-opioid receptors is also known to be involved in pain modulation. Also, studies have shown that NOP activation is involved in pain mechanisms and several behaviors related to psychological stress. Alterations in the endogenous opioid system are suspected to be involved in Parkinson's disease, seizures, neuroprotective mechanisms, and depression.

Source: www.news-medical.net ↗
02What is the concept of the immune self, and how has it evolved over the decades?

Adaptive immunity is the ability of specific lymphocytes to differentiate between self and non-self (foreign) antigens and defend the body by selectively destroying non-self-peptides. This concept is possibly the most crucial factor in several immunological medical domains and is increasingly being explored across cancer immunotherapy, vaccine design, pathogen identification, and autoimmune disorders (including allergies). A growing body of literature elucidates the importance of peptides, short amino acid chains linked via peptide bonds, in providing the adaptive immune system with the information required to effectively distinguish between self and non-self particles. This has resulted in the proposal of the ‘immune self’ concept, which postulates that self-similarity is a fundamental determinant of immune recognition. First introduced by Frank MacFarlane Burnet in 1949, the immune self-concept and its sister, the self-nonself theory, have substantially evolved over the decades. Initially driven by observations from Medawar’s early transplantation experiments, Nils K. Jerne (1974; eigen-behavior theory), Polly Matzinger (1994; danger theory), and most recently, evidence from research conducted independently by Waldmann, Mitchison, and Janeway has refined the immune self-concept from ‘all body elements are self, and foreign elements are non-self’ to the most recent ‘infectious non-self (foreign and usually harmful) versus noninfectious self (safe) elements.’

Source: www.news-medical.net ↗
03How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
04What are functional peptides?

Conventional pharmacological studies on spices have traditionally focused on secondary metabolites like polyphenols, alkaloids, and terpenes. More recently, food science research has also examined spice proteins and their enzymatic hydrolysates, using proteomic methods such as liquid chromatography–tandem mass spectrometry (LC-MS/MS) to identify short bioactive peptide sequences released from larger precursor proteins.6 Once released during food processing, fermentation, or gastrointestinal digestion, these functional peptides can act as metabolic regulators, antimicrobials, or antioxidants.1 Functional peptides refer to specific protein fragments that, once released from their parent proteins, exert biological activities.1,2 In the context of foods, these activities are most often demonstrated using in vitro biochemical or cell-based assays, and their physiological relevance depends on bioavailability and dose.2 Unlike intact proteins, which can have the potential to be allergenic or difficult to absorb due to their complex tertiary structures, functional peptides may exhibit improved bioaccessibility, and some small peptides can cross the intestinal epithelial barrier via peptide transport systems. However, absorption efficiency varies substantially by peptide sequence and digestive conditions.6 Nutriomics and mechanistic investigations have established that the bioactivity of a peptide is dictated by its physicochemical properties, particularly its amino acid composition, molecular weight, and net charge. For example, the presence of hydrophobic amino acids like proline, leucine, and valine often correlates with high antioxidant and enzyme-inhibitory activity.2,3 Smaller peptides, typically those less than three kilodaltons (kDa) in size, exhibit greater stability against proteolytic degradation in the gastrointestinal tract.3 Moreover, cationic peptides are particularly effective as antimicrobial agents through their electrostatic interactions with bacterial membranes.3

Source: www.news-medical.net ↗
05What was this study about?

It has been noted in around 20 percent of the world population suffers from some form of pain or the other. In many individuals, pain may be relieved initially with pain medications, but soon tolerance develops, and there is a decrease in the efficacy of pain relievers. One of the main symptoms of IBS seen commonly in many sufferers is chronic abdominal pain. Professor Lewis said, "All pains are complex, but gut pain is particularly challenging to treat and affects around 20 percent of the world's population. Current drugs are failing to produce effective pain relief in many patients before side effects limit the dose that can be administered." Professor Brierley echoed this statement saying, "Internal organs have a complex network of sensory nerves that have a wide array of voltage-gated ion channels and receptors to detect stimuli... The hypersensitivity of these nerves in disease often contributes to the development of pain."

Source: www.news-medical.net ↗
comparison

Comparisons

Side-by-side pages for commonly compared peptides and research compounds.

Source: peptideuniv.com
Research context

Read sources and limitations before applying a claim.

Longevity, Performance & Obesity Research

A research peptide formulation developed to investigate metabolic regulation, mitochondrial function, and nutrient-sensing pathways.

Source: mypeptidematch.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →